

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

**MEDICAL TECHNOLOGIES EVALUATION
PROGRAMME**

**Equality impact assessment – Topic selection and
scoping**

**The UroLift System for the treatment of lower urinary
tract symptoms secondary to benign prostatic
hyperplasia**

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the development of the briefing note or during the Committee meeting, and, if so, what are they?

No equality issues were identified during the development of the briefing note. It was noted that lower urinary tract symptoms secondary to benign prostatic hyperplasia are more prevalent in black men than men of white or Asian origin. This is a function of the clinical condition, not of the technology.

No equality issues were identified at the Committee meeting but it was noted that benign prostatic hyperplasia is associated with older patients, and that age is a protected characteristic under the 2010 Equality Act.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

No action required.

3. Does the scope need to highlight any potential equality issues? If so, how?

No action required.

Approved by Associate Director (name): Mark
Campbell.....

Date: [27/11/14]